Eli Lilly Sees Profit Surge Amid Diabetes and Obesity Sales Boom
Eli Lilly’s profit doubled in the fourth quarter driven by its successful diabetes and obesity treatments, Mounjaro and Zepbound. The company reported a 60% surge in Mounjaro sales to $3.53 billion, while Zepbound brought in $1.9 billion. The top-selling products are part of a growing trend of GLP-1 receptor agonists that have gained popularity due … Read more